Progress towards a needle-free hepatitis B vaccine (Q37810816)

23 August 2017

Progress towards a needle-free hepatitis B vaccine (English)

1 reference

23 August 2017

1

0 references

Olga Borges

series ordinal

4

0 references

author name string

Gerrit Borchard

series ordinal

2

1 reference

PubMed ID

21088986

23 August 2017

Maria Conceição Pedroso de Lima

series ordinal

3

1 reference

23 August 2017

19 November 2010

1 reference

23 August 2017

Pharmaceutical Research

1 reference

23 August 2017

28

1 reference

23 August 2017

5

1 reference

23 August 2017

986-1012

1 reference

Treatment of chronic hepatitis B.

23 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Microparticles for intranasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Stealth and cunning: hepatitis B and hepatitis C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Pathogenesis of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mechanisms of granule-dependent killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Particle-based vaccines for transcutaneous vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded elastic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Dendritic cells: biology of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Initiation of adaptive immune responses by transcutaneous immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immunization without needles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Needle-free vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral tolerance and regulation of mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

NALT- versus Peyer's-patch-mediated mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Nanoparticles for nasal vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Novel approaches to vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Liposomal delivery of nucleic acids in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Chitosan for mucosal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

New drug delivery systems based on chitosan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Application of chitosan microspheres for nasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Differential levels of dendritic cell maturation on different biomaterials used in combination products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Preparation of coated nanoparticles for a new mucosal vaccine delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

How to achieve sustained and complete protein release from PLGA-based microparticles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Preparation and characterization of cationic PLGA nanospheres as DNA carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Recent advances with recombinant bacterial vaccine vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Use of live attenuated bacteria to stimulate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral somatic transgene vaccination using attenuated S. typhimurium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Preferential interaction of Salmonella typhimurium with mouse Peyer's patch M cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Expression of hepatitis B virus antigens in attenuated Salmonellae for oral immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit B of Escherichia coli heat labile enterotoxin in attenuated salmonellae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

A virulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

A crucial role of macrophages in the immune responses to oral DNA vaccination against hepatitis B virus in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral hepatitis B vaccine candidates produced and delivered in plant material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immunogenicity in humans of an edible vaccine for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Expression of hepatitis B surface antigen in transgenic plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Oral immunization with hepatitis B surface antigen expressed in transgenic plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Plant-produced vaccines: promise and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Expression of hepatitis B surface antigen in transgenic banana plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Transgenic lettuce seedlings carrying hepatitis B virus antigen HBsAg

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

A needle-free approach for topical immunization: antigen delivery via vesicular carrier system(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Vesicles as tools for the modulation of skin permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Genetic detoxification of bacterial toxins: a new approach to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immunostimulatory DNA is a potent mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Production of hepatitis B surface antigen in transgenic plants for oral immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Liposomes as immunological adjuvants and vaccine carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0314-4

Elastic liposomes mediated transcutaneous immunization against Hepatitis B

21 January 2018

1 reference

12 December 2020

Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain

1 reference

12 December 2020

Encapsulation in lipospheres of the complex between butyl methoxydibenzoylmethane and hydroxypropyl-beta-cyclodextrin

1 reference

12 December 2020

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen

1 reference

12 December 2020

Bilosomes: the answer to oral vaccine delivery?

1 reference

12 December 2020

A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

1 reference

12 December 2020

CpG DNA as mucosal adjuvant

1 reference

12 December 2020

Mucosal vaccines: recent progress in understanding the natural barriers.

1 reference

12 December 2020

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

1 reference

12 December 2020

Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin

1 reference

12 December 2020

Lipid microparticles for mucosal immunization against hepatitis B

1 reference

12 December 2020

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

1 reference

12 December 2020

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice

1 reference

12 December 2020

Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)

1 reference

12 December 2020

Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2

1 reference

12 December 2020

Studies on the Mechanism of Bile Salt-Induced Liposomal Membrane Damage

1 reference

12 December 2020

Cationic transfersomes based topical genetic vaccine against hepatitis B

1 reference

12 December 2020

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

1 reference

12 December 2020

Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines

1 reference

12 December 2020

Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force

1 reference

12 December 2020

Molecular and cellular basis of immune protection of mucosal surfaces

1 reference

12 December 2020

Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg

1 reference

12 December 2020

Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity

1 reference

12 December 2020

Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain

1 reference

12 December 2020

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

12 December 2020

Oral transgenic plant-based vaccine for hepatitis B.

1 reference

12 December 2020

Immune responses to hepatitis B surface antigen following epidermal powder immunization

1 reference

12 December 2020

Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

1 reference

12 December 2020

Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues

1 reference

12 December 2020

Immunization via hair follicles by topical application of naked DNA to normal skin

1 reference

12 December 2020

Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles

1 reference

12 December 2020

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization

1 reference

12 December 2020

Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice.

1 reference

12 December 2020

Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution

1 reference

12 December 2020

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA

1 reference

12 December 2020

A plant-derived edible vaccine against hepatitis B virus.

1 reference

12 December 2020

Surface modified liposomes for nasal delivery of DNA vaccine

1 reference

12 December 2020

The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins

1 reference

12 December 2020

Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid

1 reference

12 December 2020

Driven transport of fluid vesicles through narrow pores

1 reference

12 December 2020

Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway

1 reference

12 December 2020

CpG DNA is an effective oral adjuvant to protein antigens in mice

1 reference

12 December 2020

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants

1 reference

12 December 2020

The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin

1 reference

12 December 2020

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity

1 reference

12 December 2020

Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites.

1 reference

12 December 2020

Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination

1 reference

12 December 2020

Cross-priming in health and disease.

1 reference

12 December 2020

Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

1 reference

12 December 2020

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

1 reference

12 December 2020

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

12 December 2020

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

12 December 2020

Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules

1 reference

12 December 2020

The safety of chitosan as a pharmaceutical excipient

1 reference

12 December 2020

Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein

1 reference

12 December 2020

Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen.

1 reference

12 December 2020

10.1007/S11095-010-0314-4

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21088986